MLL2/KMT2D and MLL3/KMT2C expression correlates with disease progression and response to imatinib mesylate in chronic myeloid leukemia

BACKGROUND: Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasm whose pathogenesis is linked to the Philadelphia chromosome presence that generates the BCR–ABL1 fusion oncogene. Tyrosine kinase inhibitors (TKI) such as imatinib mesylate (IM) dramatically improved the treatment eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Rabello, Doralina do Amaral, Ferreira, Vivian D’Afonseca da Silva, Berzoti-Coelho, Maria Gabriela, Burin, Sandra Mara, Magro, Cíntia Leticia, Cacemiro, Maira da Costa, Simões, Belinda Pinto, Saldanha-Araujo, Felipe, de Castro, Fabíola Attié, Pittella-Silva, Fabio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819641/
https://www.ncbi.nlm.nih.gov/pubmed/29483845
http://dx.doi.org/10.1186/s12935-018-0523-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819641/
https://www.ncbi.nlm.nih.gov/pubmed/29483845
http://dx.doi.org/10.1186/s12935-018-0523-1

Ejemplares similares